US › Healthcare

Pharming Group NV (PHAR)

US · Healthcare · Biotechnology

$10.26+4.48%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$90.2M
Revenue YoY
-3.2%
Net profit
$1.6M
Profit YoY
-65.1%
EPS
$0.02
EPS estimate
$0.20
Net margin
1.8%

EPS came in at 0.02 against a street estimate of 0.20 — a miss of 90.0%.

Key statistics

Market cap
$713.4M
P/E
72.0
Forward P/E
204.1
P/B
2.67
Book value
$3.61
EPS (TTM)
$0.14
52-week high
$21.34
52-week low
$9.62
50-day MA
$13.01
200-day MA
$15.47
Beta
0.09

Analyst view

Analysts rate Pharming Group NV a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $34.35.

Shareholding

Institutions
0.14%

Largest institutional holders

FundStake
Silverberg Bernstein Capital Management LLC0.06%
Crossmark Global Holdings, Inc.0.02%
Morgan Stanley - Brokerage Accounts0.02%
SmartHarvest Portfolios, LLC0.02%
Citadel Advisors Llc0.01%
Knoll Capital Management LP0.01%
Goss Wealth Management LLC0.00%
EverSource Wealth Advisors, LLC0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pharming Group NV — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.